XOMA : NASDAQ : Health Care
$7.27 -0.14 | -1.89%
Today's Range: 7.25 - 7.5616
Avg. Daily Volume: 72700.0
07/21/17 - 3:59 PM ET

Financial Analysis


XOMA CORP's gross profit margin for the first quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. XOMA CORP has weak liquidity. Currently, the Quick Ratio is 0.96 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 314.57% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)0.263.96
EBITDA ($mil)-8.75-13.74
EBIT ($mil)-8.9-13.95
Net Income ($mil)-10.72-8.37


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)20.0546.61
Total Assets ($mil)22.5352.61
Total Debt ($mil)26.6346.25
Equity ($mil)-31.21-7.53


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin-3366.54-346.74
EBITDA Margin-3366.53-346.74
Operating Margin-3423.08-352.17
Sales Turnover0.081.08
Return on Assets-248.03-13.78
Return on Equity0.00.0
Debt Q1 FY17 Q1 FY16
Current Ratio0.972.45
Debt/Capital-5.811.19
Interest Expense0.611.0
Interest Coverage-14.61-13.93


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)7.596.02
Div / share0.00.0
EPS-2.37-1.4
Book value / share-4.11-1.25
Institutional Own % n/a n/a
Avg Daily Volume106752.0132812.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
XOMA NM Peers 40.44   XOMA NM Peers 42.67

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

XOMA's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

XOMA's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
XOMA NM Peers 26.63   XOMA NA Peers 0.54

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

XOMA's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
XOMA NM Peers 11.07   XOMA -721.66 Peers -9.45

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

XOMA's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, XOMA is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
XOMA 29.98 Peers 176.73   XOMA -96.72 Peers 426.84

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

XOMA is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

XOMA significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades